![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Antiviral Activity and Characterization of Resistance in a Three Day Dose Ranging Study of GS-5885, a Novel HCV NS5A inhibitor
|
|
|
Reported by Jules Levin
22nd Conference of the Asian Pacific
Association for the Study of the Liver (APASL)
February 16-19, 2012
Taipei, Taiwan
KA Wong1, A Worth1, R Martin1, E Svarovskaia1, DM Brainard2, JG McHutchison2, E Lawitz3, MD Miller1, H Mo1
1Department of Clinical Virology, Gilead Sciences, Inc., Foster City, CA, USA; 2Department of Clinical Research, Gilead Sciences, Inc., Foster City, CA, USA
3Alamo Medical Research, San Antonio, TX, USA
![APASL1.gif](../images/022712/022712-3/APASL1.gif)
![APASL2.gif](../images/022712/022712-3/APASL2.gif)
![APASL3.gif](../images/022712/022712-3/APASL3.gif)
![APASL4.gif](../images/022712/022712-3/APASL4.gif)
![APASL5.gif](../images/022712/022712-3/APASL5.gif)
![APASL6.gif](../images/022712/022712-3/APASL6.gif)
![APASL7.gif](../images/022712/022712-3/APASL7.gif)
![APASL8.gif](../images/022712/022712-3/APASL8.gif)
![APASL9.gif](../images/022712/022712-3/APASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|